INTRODUCTION: With the advent and availability of targeted therapy, the treatment of advanced/metastatic renal cell carcinoma (RCC) underwent a drastic change in 2005. The effect of this change on clinical outcome within the population has not been studied. The aim of this study was to evaluate the overall survival (OS), before, and after availability of targeted therapy, for advanced RCC cases in the population-based Surveillance, Epidemiology, and End Results (SEER) cancer registry. MATERIALS AND METHODS: All advanced (regional and distant stage) RCC cases diagnosed within the 2000 to 2008 time periods were included. Because SEER does not report the exact therapy, and because targeted therapy was initially approved in 2005, we evaluated and compared the OS outcomes of advanced RCC cases diagnosed between the years 2000 and 2003 (before targeted therapy era) with that of those diagnosed between 2005 and 2008 (targeted therapy era). RESULTS: There was a significant improvement in OS for advanced RCC patients treated in the targeted therapy era (n = 12,330) compared with those treated in the era before targeted therapy (n =11,565) (median OS 20 months vs. 15 months, P = .0006). Multivariate analysis revealed that in the time period before targeted therapy, age older than 65 years, black race, and lack of nephrectomy were predictors of a shorter OS. CONCLUSION: In univariate and multivariate analysis, targeted therapy demonstrated improvement in OS. Increasing access to targeted therapies is likely to improve outcomes in advanced RCC.
INTRODUCTION: With the advent and availability of targeted therapy, the treatment of advanced/metastatic renal cell carcinoma (RCC) underwent a drastic change in 2005. The effect of this change on clinical outcome within the population has not been studied. The aim of this study was to evaluate the overall survival (OS), before, and after availability of targeted therapy, for advanced RCC cases in the population-based Surveillance, Epidemiology, and End Results (SEER) cancer registry. MATERIALS AND METHODS: All advanced (regional and distant stage) RCC cases diagnosed within the 2000 to 2008 time periods were included. Because SEER does not report the exact therapy, and because targeted therapy was initially approved in 2005, we evaluated and compared the OS outcomes of advanced RCC cases diagnosed between the years 2000 and 2003 (before targeted therapy era) with that of those diagnosed between 2005 and 2008 (targeted therapy era). RESULTS: There was a significant improvement in OS for advanced RCCpatients treated in the targeted therapy era (n = 12,330) compared with those treated in the era before targeted therapy (n =11,565) (median OS 20 months vs. 15 months, P = .0006). Multivariate analysis revealed that in the time period before targeted therapy, age older than 65 years, black race, and lack of nephrectomy were predictors of a shorter OS. CONCLUSION: In univariate and multivariate analysis, targeted therapy demonstrated improvement in OS. Increasing access to targeted therapies is likely to improve outcomes in advanced RCC.
Authors: Derek Shek; Benjamin Tomlinson; Monica Brown; Ann Brunson; Chong-Xian Pan; Primo N Lara Journal: Clin Genitourin Cancer Date: 2012-02-28 Impact factor: 2.872
Authors: Alexander C Small; Che-Kai Tsao; Erin L Moshier; Benjamin A Gartrell; Juan P Wisnivesky; James Godbold; Guru Sonpavde; Michael A Palese; Simon J Hall; William K Oh; Matthew D Galsky Journal: World J Urol Date: 2012-05-24 Impact factor: 4.226
Authors: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: David F McDermott; Meredith M Regan; Joseph I Clark; Lawrence E Flaherty; Geoffery R Weiss; Theodore F Logan; John M Kirkwood; Michael S Gordon; Jeffrey A Sosman; Marc S Ernstoff; Christopher P G Tretter; Walter J Urba; John W Smith; Kim A Margolin; James W Mier; Jared A Gollob; Janice P Dutcher; Michael B Atkins Journal: J Clin Oncol Date: 2005-01-01 Impact factor: 44.544
Authors: Robert J Motzer; Jennifer Bacik; Lawrence H Schwartz; Victor Reuter; Paul Russo; Stephanie Marion; Madhu Mazumdar Journal: J Clin Oncol Date: 2004-02-01 Impact factor: 44.544
Authors: Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri Journal: J Clin Oncol Date: 2009-10-13 Impact factor: 44.544
Authors: Michele Marchioni; Marco Bandini; Raisa S Pompe; Zhe Tian; Tristan Martel; Anil Kapoor; Luca Cindolo; Francesco Berardinelli; Alberto Briganti; Shahrokh F Shariat; Luigi Schips; Pierre I Karakiewicz Journal: Int Urol Nephrol Date: 2017-09-20 Impact factor: 2.370
Authors: Lauren L Palazzo; Deirdre F Sheehan; Angela C Tramontano; Chung Yin Kong Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-02-20 Impact factor: 4.254
Authors: Tracy L Rose; Allison M Deal; Bhavani Krishnan; Matthew E Nielsen; Angela B Smith; William Y Kim; Matthew I Milowsky Journal: Cancer Date: 2016-06-24 Impact factor: 6.860
Authors: Bishoy A Gayed; Jessica Gillen; Alana Christie; Samuel Peña-Llopis; Xian-Jin Xie; Jingsheng Yan; Jose A Karam; Ganesh Raj; Arthur I Sagalowsky; Yair Lotan; Vitaly Margulis; James Brugarolas Journal: BMC Urol Date: 2015-04-03 Impact factor: 2.264